Brodalumab: First Global Approval
| Autor: | Sarah L. Greig |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Brodalumab Antibodies Monoclonal Humanized 030207 dermatology & venereal diseases 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Japan Psoriasis Ustekinumab medicine Humans Pharmacology (medical) Psoriatic erythroderma Receptors Interleukin-17 business.industry Antibodies Monoclonal Interleukin Dermatology Life Quality Index medicine.disease Dermatology 030220 oncology & carcinogenesis Monoclonal Immunology business medicine.drug |
| Zdroj: | Drugs. 76:1403-1412 |
| ISSN: | 1179-1950 0012-6667 |
| DOI: | 10.1007/s40265-016-0634-8 |
| Popis: | Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada. This article summarizes the milestones in the development of brodalumab leading to this first approval for the treatment of psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink